Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given a consensus rating of "Buy" by the thirteen analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $50.42.

Several research firms have commented on DYN. Chardan Capital restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Oppenheimer reaffirmed an "outperform" rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $46.00 price target for the company. Finally, Baird R W raised Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th.

Insider Buying and Selling

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the transaction, the director now owns 99,652 shares of the company's stock, valued at approximately $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,742 shares of company stock valued at $1,443,246 in the last quarter. Company insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Dyne Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company's stock valued at $3,655,000 after acquiring an additional 4,236 shares during the period. Virtue Capital Management LLC lifted its position in Dyne Therapeutics by 4.4% in the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock valued at $834,000 after purchasing an additional 981 shares during the last quarter. Geode Capital Management LLC boosted its stake in Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company's stock valued at $66,802,000 after purchasing an additional 84,760 shares during the period. Barclays PLC boosted its stake in Dyne Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 207,309 shares of the company's stock valued at $7,446,000 after purchasing an additional 128,246 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Dyne Therapeutics in the 3rd quarter worth about $1,067,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Stock Down 0.3 %

Shares of DYN traded down $0.07 on Monday, hitting $23.65. 992,424 shares of the stock traded hands, compared to its average volume of 1,420,795. Dyne Therapeutics has a 1 year low of $12.33 and a 1 year high of $47.45. The stock's 50 day moving average is $28.58 and its two-hundred day moving average is $34.75. The firm has a market capitalization of $2.41 billion, a P/E ratio of -6.64 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Research analysts forecast that Dyne Therapeutics will post -3.45 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.